Use of mylk3 gene inhibitor in preparation of drug for treating castration-resistant prostate cancer

By targeting and silencing the MYLK3 gene, MYLK3 gene inhibitors significantly reduce the proliferation capacity of CRPC cells, increase their sensitivity to AR antagonists, solve the challenges of CRPC treatment, and provide a new treatment strategy.

CN121466303BActive Publication Date: 2026-06-23GUANGZHOU CUNZHONG TECHNOLOGY SERVICE CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511776308.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-11-28
Publication Date
2026-06-23
Estimated Expiration
2045-11-28

Smart Images

  • Figure CN121466303B_ABST
    Figure CN121466303B_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Methods for inducing differentiation of undifferentiated mammalian cells into osteoblasts

    US20070031940A1

  • Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same

    US20080113351A1